Alteogen (KOSDAQ:196170) disclosed on May 15 that Korea's Ministry of Food and Drug Safety (MFDS) approved Eyzenfy (code ALT-L9, ingredient aflibercept), its biosimilar of Regeneron/Bayer's Eylea, on May 14 — nearly 20 months after the September 2024 filing application. The approval covers every indication the original Eylea holds in Korea: wet age-related macular degeneration, macular edema from retinal vein occlusion (central or branch), diabetic macular edema, and vision impairment from myopic choroidal neovascularization. The filing states the company's next step is pursuing a domestic launch, without giving a date, pricing, or partner. Unlike Alteogen's ALT-B4 licensing deals, this is Alteogen's own branded product rather than a technology license, so it does not carry a milestone or royalty figure — the company frames the commercial case only qualitatively, as import substitution for the originator product and a lower price point that could expand patient access.